Roche's Emicizumab Progresses Against Hemophilia's Next Big Challenge: Patients With Factor VIII Inhibitors
Interim results from the first patients enrolled in the Phase III HAVEN 2 study suggest Roche’s potential anti-hemophilia monoclonal antibody emicizumab reduces bleeds over time in younger as well as in older patients with inhibitors to factor VIII.
You may also be interested in...
The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.
Updates for a range of new therapies from Roche, Alnylam, BioMarin and Spark Therapeutics at the ISTH meeting in Berlin show progress in development of new hemophilia alternatives, with more late-stage programs kicking off.
Roche believes it can address thrombotic safety issues that cropped up with bispecific antibody emicizumab by providing regulators with guidance on dosing.